> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Quviviq
- URL: https://www.fdaweb.com/regulatory-review-period-for-quviviq/
- Published: 2024-09-24T12:00:00.000Z
- Updated: 2026-09-14T14:42:07.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157840

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Idorsia Pharmaceuticals’ Quviviq (daridorexant hydrochloride), indicated for treating adult patients with insomnia characterized by difficulties with sleep onset or sleep maintenance. The regulatory review period is 2,115 days, of which 1,660 days occurred during the testing phase and 455 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-09-24/pdf/2024-21836.pdf?ref=fdaweb.com).